Bovenschen H J, Tjioe M, Vermaat H, de Hoop D, Witteman B M J, Janssens R W A, Stoof T J, van de Kerkhof P C M
Department of Dermatology, Radboud University Nijmegen Medical Centre, and Department of Gastroenterology, Gelderse Vallei Hospital, Ede, the Netherlands.
Br J Dermatol. 2006 May;154(5):880-4. doi: 10.1111/j.1365-2133.2006.07189.x.
Eruptive naevi have been described to potentially arise in immune compromised patients.
We describe three patients with eruptive benign melanocytic naevi during a phase of immunosuppressive therapy. METHODS/DIAGNOSIS: Two patients with Crohn disease were treated with either azathioprine monotherapy or a combination of azathioprine and infliximab, when eruptive naevi arose particularly at the palms and soles. Our third patient with plaque psoriasis developed eruptive naevi during two episodes of treatment: during a course with the biological agent alefacept and during etanercept therapy.
We conclude that treatment with the recently available biological agents might be associated with the formation of eruptive naevi. Although positive evidence for the occurrence of malignant pigmented lesions is lacking, alertness to the development of eruptive melanocytic naevi during treatment with biological agents is indicated.
已有报道称免疫功能低下的患者可能出现发疹性痣。
我们描述了3例在免疫抑制治疗阶段出现发疹性良性黑素细胞痣的患者。
方法/诊断：2例克罗恩病患者在接受硫唑嘌呤单药治疗或硫唑嘌呤与英夫利昔单抗联合治疗时，尤其在手掌和脚底出现了发疹性痣。我们的第3例斑块状银屑病患者在两次治疗期间出现了发疹性痣：一次是在使用生物制剂阿法赛特治疗过程中，另一次是在使用依那西普治疗期间。
我们得出结论，使用最近可用的生物制剂进行治疗可能与发疹性痣的形成有关。尽管缺乏恶性色素性病变发生的阳性证据，但在使用生物制剂治疗期间仍需警惕发疹性黑素细胞痣的出现。
